
    
      Phase 2b study will be conducted with the aim of investigating the efficacy and safety of
      three fixed doses of Bavisant (0.5, 1 and 3 mg/d) compared to placebo for the treatment of
      excessive daytime sleepiness (EDS) in subjects with Parkinson's disease.
    
  